Literature DB >> 15210869

Probing the world of cytochrome P450 enzymes.

Reginald F Frye1.   

Abstract

Variability in drug response can be attributed in part to variability in the activity of drug-metabolizing enzymes. One of the most important drugmetabolizing enzyme systems in humans is the cytochrome P450 (CYP) enzyme family, which is responsible for the oxidative metabolism of numerous endogenous compounds and xenobiotics. The clinical relevance of factors that influence CYP-mediated metabolism can be appreciated by estimating in vivo enzyme activity (i.e., the phenotype) through the use of "probe drugs," which are drugs predominately or exclusively metabolized by an individual CYP enzyme. Thus, the use of probe drugs alone or in combination (i.e., the cocktail approach) can provide an invaluable tool to explore the clinical relevance of genetic and nongenetic factors that affect CYP enzyme activity and thereby contribute substantially to variability in response to therapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210869     DOI: 10.1124/mi.4.3.5

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  13 in total

1.  Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.

Authors:  Jiangquan Zhou; Philip E Empey; Robert R Bies; Patrick M Kochanek; Samuel M Poloyac
Journal:  Drug Metab Dispos       Date:  2011-08-25       Impact factor: 3.922

2.  Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.

Authors:  N K Zgheib; R F Frye; T S Tracy; M Romkes; R A Branch
Journal:  Br J Clin Pharmacol       Date:  2006-10-19       Impact factor: 4.335

3.  Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.

Authors:  Daniel L Hertz; Christine M Walko; Arlene S Bridges; J Heyward Hull; Jill Herendeen; Kristan Rollins; Paul B Watkins; E Claire Dees
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

4.  Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.

Authors:  Parul Gor; Yazen Alnouti; Gregory A Reed
Journal:  J Pharm Biomed Anal       Date:  2011-04-09       Impact factor: 3.935

5.  The influence of a newly developed quinolone: antofloxacin, on CYP activity in rats.

Authors:  Xiao Xu; Hai-Yan Liu; Li Liu; Lin Xie; Xiao-Dong Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jan-Mar       Impact factor: 2.441

6.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

7.  Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats.

Authors:  Li Liu; Ming-xing Miao; Ze-yu Zhong; Ping Xu; Yang Chen; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

8.  Deoxyschizandrin, a naturally occurring lignan, is a specific probe substrate of human cytochrome P450 3A.

Authors:  Jingjing Wu; Yunfeng Cao; Yanyan Zhang; Yong Liu; James Y Hong; Liangliang Zhu; Guangbo Ge; Ling Yang
Journal:  Drug Metab Dispos       Date:  2013-10-16       Impact factor: 3.922

9.  Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach.

Authors:  Ang Chen; Xiaojing Zhou; Shuowen Tang; Mingyao Liu; Xin Wang
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

10.  Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.

Authors:  Catherine Dutreix; Sebastien Lorenzo; Yanfeng Wang
Journal:  Eur J Clin Pharmacol       Date:  2014-05-21       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.